Immunotherapy for lung cancer — how it works, and who it helps

Immunotherapy is a treatment that helps your own immune system find and attack cancer. Healthy immune cells are very good at spotting threats, but lung cancer can hide by pressing a kind of "brake" on these cells so they leave the tumour alone. The most common immunotherapy drugs — called immune checkpoint inhibitors — release that brake, so your immune system can recognise the cancer and fight it.

The brake these drugs target is a pathway called PD-1 / PD-L1. Cancer cells often show a protein called PD-L1 on their surface that switches off nearby immune cells. Checkpoint inhibitors block this signal, which is why testing your tumour for PD-L1 helps your team decide whether immunotherapy is likely to help. This is different from chemotherapy, which attacks fast-growing cells directly, and from targeted therapy, which matches a specific gene change.

Immunotherapy is used most in non-small cell lung cancer (NSCLC) — including adenocarcinoma and squamous cell lung cancer — and also has a role in some small cell lung cancers. Depending on your stage and PD-L1 level, it may be given:

• On its own — when the PD-L1 level is high and no targetable gene change is found
• With chemotherapy — a combination often used when PD-L1 is lower
• After surgery or radiation — to lower the chance of the cancer returning in some earlier-stage cases
• With radiation in stage 3 — immunotherapy can follow chemo-radiation to help keep the cancer controlled

Immunotherapy is not right for everyone, and it does not replace surgery, radiation, chemotherapy, or targeted tablets — it is one tool among several. At CION, your tumour board weighs all of these together, so the plan fits your exact cancer rather than a single fixed protocol.

1. 1

   The cancer type and stage are confirmed

   Immunotherapy decisions depend on whether you have NSCLC or small cell lung cancer, and on the stage. This comes from your biopsy and scans, so the foundation is solid before treatment is chosen.

2. 2

   PD-L1 and other biomarkers are tested

   Your tumour tissue is tested for PD-L1, usually alongside other markers such as EGFR and ALK. A targetable gene change often means a tablet is tried first, while the PD-L1 level helps judge how well immunotherapy may work. Read more about PD-L1 and molecular testing.

3. 3

   The tumour board chooses the approach

   A panel of medical, surgical, and radiation oncologists decides together whether immunotherapy should be given alone, with chemotherapy, or after other treatment. This shared decision means your plan is not one doctor's opinion.

4. 4

   Treatment is given as a drip

   Checkpoint inhibitors are given as an infusion into a vein, usually every two to six weeks in a day-care setting. Most sessions take under an hour, and you go home the same day. The schedule is planned around your life as much as possible.

5. 5

   Response and side effects are monitored

   Scans check whether the cancer is responding, and your team watches closely for immune-related side effects. If something needs adjusting, it is caught early — and every step is explained to you in a 45-minute consultation, so nothing is rushed.

This table is a guide, not a prescription. The right choice always comes from your full picture — scans, biopsy, biomarkers, and your own wishes — reviewed by the tumour board. See how this fits the wider plan in lung cancer treatment in Hyderabad.

It is natural to ask about lung cancer immunotherapy success rates. The honest answer is that results vary a great deal from person to person, and no doctor can promise an outcome in advance. What we can say is that, for some people with advanced lung cancer, immunotherapy controls the cancer for far longer than older treatments did — and a smaller group see a deep, lasting response. For others, it helps less, or not at all, which is why response is monitored closely with scans.

Several things shape how well immunotherapy for NSCLC may work: the PD-L1 level, the cancer type and stage, whether a targetable gene change is present, and your general health. A higher PD-L1 level tends to suggest a better chance of benefit, but it is not a guarantee on its own. Because of this, your team sets realistic expectations with you from the start, rather than offering numbers that may not apply to your situation.

At CION, we believe honesty is part of good care. We will tell you what immunotherapy can and cannot do for your specific cancer, review your response together, and change course if it is not working. That is what we mean by decisions for healing, not billing — and why we never make promises medicine cannot keep.

Tell your team about any new symptom, even a small one — with immunotherapy, early action keeps most side effects mild. This careful monitoring is part of how CION keeps treatment as safe and comfortable as possible.

Whether immunotherapy is right for you is not a simple yes-or-no. It depends on your cancer type, stage, PD-L1 level, biomarkers, and your own health and wishes. At CION, every one of these is reviewed by a tumour board — medical, surgical, and radiation oncologists deciding together — so no single opinion sets your course. You then sit with a doctor for a 45-minute consultation to talk it all through.

Our team brings 150+ years of combined experience and 17 super-specialist oncologists across 35+ centres in Telangana and Andhra Pradesh. We test what genuinely changes the plan, explain costs clearly, and never push a treatment that will not help. If immunotherapy is the right path for you, we guide it carefully; if it is not, we say so honestly and explain what is.

When you are ready, meet our lung cancer specialists in Hyderabad, understand the tests behind the decision in molecular and PD-L1 testing, or see how everything fits in lung cancer treatment in Hyderabad. You deserve a plan built for your healing.

Guided through treatment by a team that explains everything

Patients across Telangana and Andhra Pradesh share what it felt like to have their options explained honestly, and to be guided with care at CION.